RLS clinical trial - ChloraSolv01 – is completed and the result is to be analyzed

RLS Global is pleased to announce that the database for ChloraSolv01 is closed and RLS has received the first statistical report and results. ChloraSolv01 is a pilot study in which the patient with chronic ulcers on the lower leg or foot is treated with ChloraSolv for five weeks. The study endpoints include for example the reduction of devitalized tissue (necrotic tissue) and reduction of wound size.


One important reason for the implementation of the study is to obtain clinical data, to regulatory broaden the indication of use for ChloraSolv, from diabetic foot ulcers to other types of chronic ulcers (venous leg ulcers, mixed ulcers etc.). Due to ChloraSolv01, RLS has now the relevant data and will apply for the broader indication at the company’s notified body, Eurofins which will increase the market potential for ChloraSolv.
 

“The results are according to the expectations”, confirms Karin Fischer – CEO of RLS Global. Karin continues, “these data reinforce our belief that ChloraSolv has great ability to clean both necrotic tissue and bacteria in a fast and gentle manner. The number of reported adverse events are few and none related to the product”.


The data will be further analyzed, and the clinical publication will be compiled by principal investigator, Senior Consultant, Associate Professor Jan Apelqvist, together with the other investigators from the study. In parallel to the publication in a medical journal, RLS will present part of the results at international conferences in the fall of 2020.
 

RLS takes the opportunity to thank all the staff and the healthcare institutions that participated in ChloraSolv01. 

Contact information
Karin Fischer, CEO
E-mail:
karin.fischer@rlsglobal.se
Telephone: +46 702-48 46 51

Mats Ahlenius, CTO
E-mail: mats.ahlenius@rlsglobal.se
Telephone: +46 70 741 03 39

Trading place and Certified Advisor
RLS Global’s shares has been listed on the Nasdaq First North Growth Market since 17th May, 2017 and trading takes place under the short name RLS. Certified Advisor is Redeye Aktiebolag, phone: +46 8 121 576 90, email: certifiedadviser@redeye.se. During the period 2012 - 2017, the company was listed on Aktietorget.

Publication
RLS Global AB (publ) is obliged to make the information contained herein public pursuant to the EU market abuse regulation. The information was submitted for publication through the agency of the above contact person, at 09.00 CET on July 9th, 2020

About RLS Global AB
RLS Global AB is a medical technology company within Life Science. Based on the company's unique hypochlorite platform, RLS Global develop products for some of our most common illnesses in wound and oral care. RLS Global has a portfolio of strong brands, including ChloraSolv® and Carisolv®. The company is listed on Nasdaq First North Growth Market. Certified Advisor is Redeye Aktiebolag, phone: +46 8 121 576 90, email: certifiedadviser@redeye.se Read more at www.rls.global

About Us

For many years, RLS Global has worked with Oral Care specialists, pioneering new therapies for Oral Care and their patients. We are now taking another major step toward easier and more effective care within Wound Care. We will continue to work with Healthcare Professionals to ensure to develop a treatment that further helps deliver the best care for each patient. The method is clinically proven and saves the patient a lot of suffering. Our focus is on caring for patients, developing efficient and safe products that offer gentle treatment methods.